Treatment
Adalimumab clinical trials
We’re tracking 34 recruiting studies that include Adalimumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07622771RecruitingPhase 2
Radiation, chemotherapy, and immunotherapy for advanced rectal cancer
This trial tests a combination of radiation therapy, a chemotherapy drug called NALIRIFOX, and an immunotherapy drug called adebrelimab for rectal cancer that has grown into nearby tissue or lymph nodes. The goal is to see if this combination helps shrink the tumor before surgery and improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT02706704RecruitingPhase 2
Adalimumab eye injections vs under-skin shots for uveitis
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
BeirutAges 18 years+ - NCT06180382RecruitingPhase 4
Comparing vedolizumab to higher-dose adalimumab for Crohn's disease
This trial tests whether switching to vedolizumab works better than increasing your adalimumab dose if your Crohn's symptoms or inflammation are coming back despite treatment. It aims to find the best next step for people whose condition is no longer well-controlled.
Le Kremlin-Bicêtre, PARISAges 18 years+ - NCT04300686RecruitingPhase 4
Pilot study for severe Takayasu artery inflammation
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
Shanghai, Shanghai MunicipalityAges 14–100 - NCT04183608RecruitingPhase 4
Telemonitoring and education to guide treatment for ulcerative colitis
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
Cholet, Maine Et LoireAges 18–75 - NCT07845604RecruitingPhase 2
Testing an anti-inflammatory drug with Lexapro for depression
This study tests whether an anti-inflammatory medication (adalimumab, also known as Humira) can help treat depression when added to Lexapro. It may help people whose depression is linked to higher levels of inflammation in the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07663331RecruitingPhase 4
Adalimumab for adults with non-infectious uveitis
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07564505RecruitingPhase 4
Adalimumab Safety and Effectiveness in Children With Crohn's Disease
This study tracks how well and how safely a medicine called adalimumab works in children ages 6–17 with moderate-to-severe Crohn's disease (a condition causing inflammation in the digestive tract). Your child's doctor has already decided adalimumab is appropriate for them, and this study simply collects information about how they respond to it.
Guangzhou, GuangdongAges 6–17 - NCT07510191RecruitingPhase 4
Comparing two ways to treat Crohn's disease if TNFi isn't working well
This trial tests if adding a low dose of a newer pill (upadacitinib) to your current TNF inhibitor (TNFi) works better than increasing the dose of your TNFi alone. It is for people with Crohn's disease who have had some improvement on their TNFi but still have active disease.
Guangzhou, GuangdongAges 18–65 - NCT07061574RecruitingPhase 1/Phase 2
Immune treatment for new onset type 1 diabetes
This study tests a low dose of a drug that calms the immune system, followed by either another immune drug or a blood pressure medicine, to see if they can help preserve the body's ability to make insulin in people recently diagnosed with type 1 diabetes. It may help keep your own insulin production going longer.
San Francisco, CaliforniaAges 9–20 - NCT03938701RecruitingPhase 2
Imaging gut and joint inflammation with adalimumab and a light tracer
This study uses a special “light tracer” medicine with adalimumab to see where inflammation is in the gut (IBD) or joints (RA). If you have active disease, it may help doctors better target treatment by showing inflammation more clearly during scans.
Groningen, Provincie GroningenAges 18 years+ - NCT06100744RecruitingPhase 3
Comparing two drugs for children with psoriatic arthritis
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Little Rock, ArkansasAges 5–17 - NCT06045754RecruitingPhase 4
Study of vedolizumab with other drugs for Crohn's disease
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
Dothan, AlabamaAges 18–70 - NCT06037811RecruitingPhase 2
Adalimumab for Immunotherapy-Related Arthritis
This study tests if a medicine called adalimumab (a type of TNF blocker) can help with new joint pain and swelling (inflammatory arthritis) caused by some immunotherapy drugs. It aims to reduce the need for high-dose steroids and improve symptoms.
London, OntarioAges 18 years+ - NCT05626348RecruitingPhase 4
Test immune-modulator treatments for rheumatoid arthritis with knee trouble
This Phase 4 trial studies whether immune-modulator medicines improve symptoms and function in people with rheumatoid arthritis who have knee problems. It may also compare responses in osteoarthritis and healthy volunteers, depending on the group you fit.
Jinan, ShandongAges 18–80 - NCT05503875Recruiting
Study uses psoriasis “immune patterns” to guide treatment
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
Hangzhou, ZhejiangAges 18–75 - NCT04725422Recruiting
Registry for children with nonbacterial bone inflammation
This study collects medical information (and imaging results) from children and teens with nonbacterial bone inflammation. It may help doctors better understand how this condition looks on scans and how it’s diagnosed, especially to rule out infection or cancer.
Seattle, WashingtonAges Up to 21 years - NCT06498089RecruitingPhase 4
Comparing tailored vs. standard treatment for active Takayasu's arteritis.
This trial compares a personalized treatment plan based on your specific disease markers to standard care, aiming to find which is more effective and safer for active Takayasu's arteritis. It may help researchers learn how to better control inflammation and prevent flares.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07694674Recruiting
Comparing Biologic Drugs to Prevent Crohn's Return After Surgery
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07663526RecruitingPhase 4
Tabellvi for moderate to severe Crohn's disease in adults
This trial tests Tabellvi (adalimumab) for adults with moderate to severe Crohn's disease who haven't responded well to steroids or other treatments. It aims to see if this medication can help control symptoms and improve quality of life.
Fuyang, AnhuiAges 18–70 - NCT06062875RecruitingPhase 2
Testing a drug for enlarged prostate symptoms
This trial tests whether a drug called adalimumab (a TNF blocker) can improve symptoms of an enlarged prostate. It is for men aged 45-80 with a large prostate and bothersome urinary symptoms who have not used this type of medication before.
Glenview, IllinoisAges 45–80 - NCT01706692Recruiting
Study registry for targeted treatments in psoriasis patients
This trial is a registry that collects information from adults with plaque psoriasis or psoriatic arthritis who are starting a new biologic or other systemic treatment. It helps researchers understand how these treatments are used in real life and what outcomes they may have.
AarauAges 18 years+ - NCT07491913Recruiting
Stopping biologic therapy for Takayasu arteritis in stable patients
This study looks at whether it is safe for people with Takayasu arteritis to stop taking their biologic medication (like TNF inhibitors or tocilizumab) if they have been in remission—meaning their disease has been quiet—for a long time. You might join this trial if your condition has been stable for years and you haven't needed steroids lately.
IstanbulAges 18 years+ - NCT07423533RecruitingPhase 2
GenSci120 injection for moderate to severe rheumatoid arthritis
This trial tests a new injection called GenSci120 for people with moderate to severe rheumatoid arthritis who haven't improved enough after trying at least one standard arthritis medication. The goal is to see if this treatment can help reduce joint pain and swelling.
Beijing, Beijing MunicipalityAges 18–70
What Adalimumab is being studied for
Conditions with recruiting Adalimumab studies.
Common questions
- Are there clinical trials studying Adalimumab?
- Yes. Clin2 currently lists 34 recruiting studies that include Adalimumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Adalimumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Adalimumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Adalimumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.